Identification of High-Risk Population for Mortality and Severe Clinical Outcomes Among Patients With Myasthenia Gravis: A Nationwide Population-Based Cohort Study in Korea
Our study identified high-risk populations among patients with MG. Patients with a history of certain clinical criteria, including MC or refractory MG, had elevated risk of mortality and severe clinical outcomes. These findings may be utilized to establish the reimbursement strategy by identifying MG patients with a priority need for new treatments.
Authors
- Jin Sung Yuk
- Ha Young Shin (ORCID: https://orcid.org/0000-0002-4408-8265)
- Jieun Woo (ORCID: https://orcid.org/0009-0004-1328-2470)
- Ju Hwan Kim (ORCID: https://orcid.org/0000-0001-7253-6515)
- Ju‐Young Shin (ORCID: https://orcid.org/0000-0003-1010-7525)
- Yongtai Cho (ORCID: https://orcid.org/0000-0003-3303-7881)
- Y.S. Park
- Seung Woo Kim (ORCID: https://orcid.org/0000-0002-5621-0811)
- Kyungyeon Jung
Institutions
- Yonsei University (KR)
- UCB Pharma (France) (FR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Journal of Korean Medical Science
- Published
- 2025-01-01
- DOI
- https://doi.org/10.3346/jkms.2025.40.e240
- Citations
- 1
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Pfizer
- AstraZeneca
- Sanofi
- Biogen
- Alexion Pharmaceuticals
- Myung In Pharm
- Yuhan
- National Research Foundation
- Ministry of Food and Drug Safety
- National Research Foundation of Korea
- Daewoong Pharmaceutical Company
- Astellas Pharma